Literature DB >> 12435771

The risk of aseptic meningitis associated with the Leningrad-Zagreb mumps vaccine strain following mass vaccination with measles-mumps-rubella vaccine, Rio Grande do Sul, Brazil, 1997.

Claudio Marcos da Silveira1, Claudete Iris Kmetzsch, Renate Mohrdieck, Alethea Fagundes Sperb, D Rebecca Prevots.   

Abstract

BACKGROUND: Few data are available on the risk of aseptic meningitis following vaccination with the Leningrad-Zagreb (L-Z) strain of mumps vaccine. In 1997 the mumps vaccine was introduced into the state of Rio Grande do Sul in Brazil through mass vaccination with mumps-measles-rubella (MMR), targeting children aged 1-11 years. Five municipalities used exclusively MMR vaccine containing the L-Z strain of mumps. An outbreak of aseptic meningitis was observed shortly after the mass campaign.
METHODS: To estimate the risk of aseptic meningitis associated with this strain, we analysed vaccination and meningitis case surveillance data from the selected municipalities. A case of vaccine-associated aseptic meningitis was defined as one with a pleocytosis of 10-1,500 leukocytes/ml and occurring within 15-35 days after vaccine receipt.
RESULTS: We estimated a risk of 2.9 cases per 10,000 doses of L-Z administered, equivalent to 1 case per 3,390 doses administered. The overall risk of aseptic meningitis following the campaign was increased 12.2-fold (95% CI: 6.0-24.7) compared with the same period in 1995-1996. Following the mass campaign, the incidence of mumps declined 93% during 1998-2000.
CONCLUSIONS: Vaccination with the L-Z strain of mumps vaccine as part of a mass campaign was associated with a significantly increased risk of aseptic meningitis. Decisions about type of mumps vaccine and mumps vaccination strategies must consider vaccine safety issues in addition to other criteria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435771     DOI: 10.1093/ije/31.5.978

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  10 in total

Review 1.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 2.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

Review 3.  Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.

Authors:  Keri Wellington; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

Authors:  Silvia Perez-Vilar; Daniel Weibel; Miriam Sturkenboom; Steven Black; Christine Maure; Jose Luis Castro; Pamela Bravo-Alcántara; Caitlin N Dodd; Silvana A Romio; Maria de Ridder; Swabra Nakato; Helvert Felipe Molina-León; Varalakshmi Elango; Patrick L F Zuber
Journal:  Vaccine       Date:  2017-05-27       Impact factor: 3.641

5.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

6.  Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.

Authors:  Ashwani Sood; Monjori Mitra; Himanshu Arvind Joshi; Uma Siddhartha Nayak; Prashanth Siddaiah; T Ramesh Babu; Samarendra Mahapatro; Jayesh Sanmukhani; Gaurav Gupta; Ravindra Mittal; Reinhard Glueck
Journal:  Hum Vaccin Immunother       Date:  2017-03-31       Impact factor: 3.452

Review 7.  Mumps in the Vaccination Age: Global Epidemiology and the Situation in Germany.

Authors:  Andrea-Ioana Beleni; Stefan Borgmann
Journal:  Int J Environ Res Public Health       Date:  2018-07-31       Impact factor: 3.390

8.  A Single Point Mutation in the Mumps V Protein Alters Targeting of the Cellular STAT Pathways Resulting in Virus Attenuation.

Authors:  Tahir Malik; Laurie Ngo; Trent Bosma; Steven Rubin
Journal:  Viruses       Date:  2019-11-01       Impact factor: 5.048

9.  Immune response to the mumps component of the MMR vaccine in the routine of immunisation services in the Brazilian National Immunisation Program.

Authors:  Eliane Matos dos Santos; Gloria Regina da Silva e Sá; Marilda Mendonça Siqueira; Reinaldo de Menezes Martins; Luiz Antonio Bastos Camacho; Vanessa dos Reis von Doellinger; Maria de Lourdes de Sousa Maia
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-05-07       Impact factor: 2.743

10.  Case report: aseptic meningitis secondary to varicella-zoster virus (VZV) without an exanthem post MMR vaccination.

Authors:  Syeda Sahra; Abdullah Jahangir; Allison Glaser; Neville Mobarakai; Ahmad Jahangir
Journal:  BMC Infect Dis       Date:  2021-08-03       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.